PTC Therapeutics, Inc. PTCT
64.14 USD -0.89 (-1.37%)
At closeNov 10, 2026, 5:31 PM EST
64.14 0.00 0.00%
After hours · Nov 10, 5:31 PM ET
63.52 Day range 65.15
58.80 52-week range 90.87
- YTD
- -15.56%
- 1 year
- -11.51%
News
seekingalpha.com PTC Therapeutics: Sephience Keeps Beating The Forecast, But The Price Already Knows PTC Therapeutics (PTCT) is rated Hold, bordering on Sell, with fair value estimated at $52/share versus a $59.97 current price. Sephience's strong launch drives growth, but legacy product declines…
benzinga.com PTC Therapeutics Board Authorizes $500M Share Repurchase Program PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of the Company's…
prnewswire.com PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase…
benzinga.com Citigroup Maintains Buy on PTC Therapeutics, Raises Price Target to $109 Citigroup analyst Eric Joseph maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $108 to $109.
prnewswire.com PTC Therapeutics to Participate in Upcoming Investor Conferences WARREN, N.J., Nov. 2, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Jefferies Global Healthcare Conference…
prnewswire.com PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of…- benzinga.com TD Cowen Maintains Buy on PTC Therapeutics, Raises Price Target to $95 TD Cowen analyst Joseph Thome maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $90 to $95.
- benzinga.com RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $77 RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $75 to $77.
benzinga.com Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $112 Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $109 to $112.
seekingalpha.com PTC Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call Transcript PTC Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call Transcript
marketbeat.com PTC Therapeutics Q3 Earnings Call Highlights PTC Therapeutics NASDAQ: PTCT reported third-quarter 2026 total revenue of $358 million, including $276 million in net product revenue, as sales of phenylketonuria treatment Sephience continued to…
zacks.com PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall…
zacks.com PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates PTC Therapeutics (PTCT) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.2 per share a year ago.
benzinga.com PTC Therapeutics Q3 2026 Earnings Call Transcript PTC Therapeutics (NASDAQ:PTCT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com CORRECTION: PTC Therapeutics Q3 Adj. EPS $0.94 Beats $0.34 Estimate, Sales $357.807M Beat $306.399M Estimate PTC Therapeutics (NASDAQ:PTCT) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.34 by 176.47 percent. This is a 370 percent increase over earnings of…
benzinga.com PTC Therapeutics Raises FY2026 Sales Guidance from $1.180B-$1.280B to $1.290B-$1.320B vs $1.262B Est PTC Therapeutics (NASDAQ:PTCT) raises FY2026 sales outlook from $1.180 billion-$1.280 billion to $1.290 billion-$1.320 billion vs $1.262 billion estimate.
prnewswire.com PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results – Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with…
zacks.com Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
defenseworld.net PTC Therapeutics (NASDAQ:PTCT) Director Sells $149,025.00 in Stock PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) Director Michael Schmertzler sold 2,500 shares of the stock in a transaction on Wednesday, October 14th. The stock was sold at an average price…
prnewswire.com PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026 WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2026 financial…- benzinga.com RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75 RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price target from $85 to $75.
defenseworld.net PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 435 Shares of Company Stock PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) VP Mark Boulding sold 435 shares of the company's stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of…
defenseworld.net Comparing PTC Therapeutics (NASDAQ:PTCT) and Precigen (NASDAQ:PGEN) Precigen (NASDAQ: PGEN - Get Free Report) and PTC Therapeutics (NASDAQ: PTCT - Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will contrast the two…
defenseworld.net PTC Therapeutics (NASDAQ:PTCT) Shares Climb 4.7% – Here’s Why Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) shot up 4.7% during trading on Monday. The stock traded as high as $65.75 and last traded at $65.60. 659,183 shares were traded…
prnewswire.com PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept.
benzinga.com Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137 Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $130 to $137.
prnewswire.com PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy – Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced…
seekingalpha.com PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
defenseworld.net Amundi Raises Holdings in PTC Therapeutics, Inc. $PTCT Amundi grew its stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 171.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and…
defenseworld.net California State Teachers Retirement System Has $543.82 Million Stock Position in PTC Therapeutics, Inc. $PTCT California State Teachers Retirement System raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 7,806.7% during the undefined quarter, according to the company in its most recent…- benzinga.com PTC Therapeutics To Present New Sephience Data At The 2026 Society For The Study Of Inborn Errors Of Metabolism Annual Symposium, August 25-28 The presentations include new data from clinical trials and real-world evidence which reinforce the clinically meaningful benefits of Sephience on lowering phenylalanine (Phe), significant diet…
benzinga.com Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122 Barclays analyst Eliana Merle maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $120 to $122.
benzinga.com PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity' PTC Therapeutics plans to acquire Sangamo’s ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.- benzinga.com Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109 Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $106 to $109.
benzinga.com PTC Therapeutics To Acquire BLA-Stage ST-920 Fabry Disease Program; Terms Include $111M Upfront And Up To $100M In Contingent Milestone Payments Based On Certain Regulatory Approvals Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization –– ST-920 is a one-time administered AAV gene therapy…
benzinga.com Top 3 Health Care Stocks You'll Regret Missing This Quarter The most oversold health care stocks present a buying opportunity. RSI indicator compares stock strength on up and down days, indicating short-term performance. Here's the latest list of oversold…- benzinga.com Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104 Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $93 to $104.
- benzinga.com Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106 Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $93 to $106.
- benzinga.com PTC Therapeutics Raises FY2026 Sales Guidance from $1.080B-$1.180B to $1.180B-$1.280B vs $1.196B Est PTC Therapeutics (NASDAQ:PTCT) raises FY2026 sales outlook from $1.080 billion-$1.180 billion to $1.180 billion-$1.280 billion vs $1.196 billion estimate.
- benzinga.com Wells Fargo Maintains Overweight on PTC Therapeutics, Lowers Price Target to $93 Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price target from $95 to $93.
benzinga.com Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $130 Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $124 to $130.- benzinga.com RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $85 RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $82 to $85.
benzinga.com 8 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com PTC Therapeutics Announces Proposed Private Placement Of $500M Of Convertible Senior Notes Due 2031 PTC intends to grant the initial purchasers an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to $50.0 million of additional…- benzinga.com Jefferies Upgrades PTC Therapeutics to Buy, Raises Price Target to $85 Jefferies analyst Faisal Khurshid upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and raises the price target from $76 to $85.
- benzinga.com TD Cowen Upgrades PTC Therapeutics to Buy, Raises Price Target to $90 TD Cowen analyst Joseph Thome upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and raises the price target from $75 to $90.
- benzinga.com RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $82 RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $81 to $82.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $95 Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $86 to $95.
- benzinga.com PTC Therapeutics Raises FY2026 Sales Guidance from $700.000M-$800.000M to $1.080B-$1.180B vs $1.013B Est PTC Therapeutics (NASDAQ:PTCT) raises FY2026 sales outlook from $700.000 million-$800.000 million to $1.080 billion-$1.180 billion vs $1.013 billion estimate.